{"id":687960,"date":"2022-09-22T08:04:11","date_gmt":"2022-09-22T12:04:11","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/alzamend-neuro-has-regained-compliance-with-nasdaqs-minimum-bid-price-requirement\/"},"modified":"2022-09-22T08:04:11","modified_gmt":"2022-09-22T12:04:11","slug":"alzamend-neuro-has-regained-compliance-with-nasdaqs-minimum-bid-price-requirement","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/alzamend-neuro-has-regained-compliance-with-nasdaqs-minimum-bid-price-requirement\/","title":{"rendered":"Alzamend Neuro Has Regained Compliance with Nasdaq’s Minimum Bid Price Requirement"},"content":{"rendered":"

<\/p>\n

Alzamend Neuro Has Regained Compliance with Nasdaq’s Minimum Bid Price Requirement<\/b><\/p>\n

ATLANTA–(BUSINESS WIRE<\/a>)–Alzamend Neuro, Inc.<\/a> (Nasdaq: ALZN) (\u201cAlzamend\u201d), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer\u2019s disease (\u201cAlzheimer\u2019s\u201d), bipolar disorder, major depressive disorder (\u201cMDD\u201d) and post-traumatic stress disorder (\u201cPTSD\u201d), today announced that it has received a notification letter (the \u201cCompliance Notice\u201d) from the Listing Qualifications Staff of the Nasdaq Stock Market, LLC (\u201cNasdaq\u201d) dated September 21, 2022, informing the Company that it has regained compliance with Nasdaq Listing Rule 5550(a)(2) (the \u201cMinimum Bid Price Requirement\u201d) and the matter is closed.\n<\/p>\n

\nAs previously announced, on June 22, 2022, Alzamend received a notification letter from Nasdaq stating that the Company was not in compliance with the Minimum Bid Price Requirement because the bid price for the Company\u2019s common stock had closed below $1.00 per share for the previous 30 consecutive business days. To regain compliance with the Minimum Bid Price Requirement, the Company was required to maintain a minimum closing bid price of the Company’s common stock of at least $1.00 for a minimum of ten consecutive business days. The Compliance Notice confirmed that the closing bid price of the Company’s common stock has been at $1.00 per share or greater for 10 consecutive business days from September 7 through September 20, 2022, the Company has regained compliance with the Minimum Bid Price Requirement.\n<\/p>\n

About Alzamend Neuro<\/b><\/p>\n

\nAlzamend is an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer\u2019s, bipolar disorder, MDD and PTSD. Our mission is to rapidly develop and market safe and effective treatments. Our current pipeline consists of two novel therapeutic drug candidates, AL001 – a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 – a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient\u2019s immunological system to combat Alzheimer\u2019s. Both of our product candidates are licensed from the University of South Florida Research Foundation, Inc. pursuant to royalty-bearing exclusive worldwide licenses.\n<\/p>\n

Forward-Looking Statements<\/b><\/p>\n

\nThis press release contains \u201cforward-looking statements\u201d within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as \u201cbelieves,\u201d \u201cplans,\u201d \u201canticipates,\u201d \u201cprojects,\u201d \u201cestimates,\u201d \u201cexpects,\u201d \u201cintends,\u201d \u201cstrategy,\u201d \u201cfuture,\u201d \u201copportunity,\u201d \u201cmay,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201ccould,\u201d \u201cpotential,\u201d or similar expressions. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties. Forward-looking statements speak only as of the date they are made, and Alzamend undertakes no obligation to update any of them publicly in light of new information or future events. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors. More information, including potential risk factors, that could affect Alzamend\u2019s business and financial results are included in Alzamend\u2019s filings with the U.S. Securities and Exchange Commission. All filings are available at www.sec.gov<\/a> and on Alzamend\u2019s website at www.Alzamend.com<\/a>.\n<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20220922005370\/en\/<\/a><\/span><\/p>\n

\nEmail: Info@Alzamend.com<\/a> or call: 1-844-722-6333\n<\/p>\n

KEYWORDS:<\/b> Georgia United States North America<\/p>\n

INDUSTRY KEYWORDS:<\/b> Biotechnology Pharmaceutical Health Mental Health<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Alzamend Neuro Has Regained Compliance with Nasdaq’s Minimum Bid Price Requirement ATLANTA–(BUSINESS WIRE)–Alzamend Neuro, Inc. (Nasdaq: ALZN) (\u201cAlzamend\u201d), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer\u2019s disease (\u201cAlzheimer\u2019s\u201d), bipolar disorder, major depressive disorder (\u201cMDD\u201d) and post-traumatic stress disorder (\u201cPTSD\u201d), today announced that it has received a notification letter (the \u201cCompliance Notice\u201d) from the Listing Qualifications Staff of the Nasdaq Stock Market, LLC (\u201cNasdaq\u201d) dated September 21, 2022, informing the Company that it has regained compliance with Nasdaq Listing Rule 5550(a)(2) (the \u201cMinimum Bid Price Requirement\u201d) and the matter is closed. As previously announced, on June 22, 2022, Alzamend received a notification letter from Nasdaq stating that the Company was not in compliance with … <\/p>\n

Continue reading “Alzamend Neuro Has Regained Compliance with Nasdaq’s Minimum Bid Price Requirement”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-687960","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nAlzamend Neuro Has Regained Compliance with Nasdaq's Minimum Bid Price Requirement - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/alzamend-neuro-has-regained-compliance-with-nasdaqs-minimum-bid-price-requirement\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Alzamend Neuro Has Regained Compliance with Nasdaq's Minimum Bid Price Requirement - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Alzamend Neuro Has Regained Compliance with Nasdaq’s Minimum Bid Price Requirement ATLANTA–(BUSINESS WIRE)–Alzamend Neuro, Inc. (Nasdaq: ALZN) (\u201cAlzamend\u201d), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer\u2019s disease (\u201cAlzheimer\u2019s\u201d), bipolar disorder, major depressive disorder (\u201cMDD\u201d) and post-traumatic stress disorder (\u201cPTSD\u201d), today announced that it has received a notification letter (the \u201cCompliance Notice\u201d) from the Listing Qualifications Staff of the Nasdaq Stock Market, LLC (\u201cNasdaq\u201d) dated September 21, 2022, informing the Company that it has regained compliance with Nasdaq Listing Rule 5550(a)(2) (the \u201cMinimum Bid Price Requirement\u201d) and the matter is closed. As previously announced, on June 22, 2022, Alzamend received a notification letter from Nasdaq stating that the Company was not in compliance with … Continue reading "Alzamend Neuro Has Regained Compliance with Nasdaq’s Minimum Bid Price Requirement"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/alzamend-neuro-has-regained-compliance-with-nasdaqs-minimum-bid-price-requirement\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-22T12:04:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20220922005370r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alzamend-neuro-has-regained-compliance-with-nasdaqs-minimum-bid-price-requirement\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alzamend-neuro-has-regained-compliance-with-nasdaqs-minimum-bid-price-requirement\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Alzamend Neuro Has Regained Compliance with Nasdaq’s Minimum Bid Price Requirement\",\"datePublished\":\"2022-09-22T12:04:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alzamend-neuro-has-regained-compliance-with-nasdaqs-minimum-bid-price-requirement\\\/\"},\"wordCount\":585,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alzamend-neuro-has-regained-compliance-with-nasdaqs-minimum-bid-price-requirement\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20220922005370r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alzamend-neuro-has-regained-compliance-with-nasdaqs-minimum-bid-price-requirement\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alzamend-neuro-has-regained-compliance-with-nasdaqs-minimum-bid-price-requirement\\\/\",\"name\":\"Alzamend Neuro Has Regained Compliance with Nasdaq's Minimum Bid Price Requirement - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alzamend-neuro-has-regained-compliance-with-nasdaqs-minimum-bid-price-requirement\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alzamend-neuro-has-regained-compliance-with-nasdaqs-minimum-bid-price-requirement\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20220922005370r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2022-09-22T12:04:11+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alzamend-neuro-has-regained-compliance-with-nasdaqs-minimum-bid-price-requirement\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alzamend-neuro-has-regained-compliance-with-nasdaqs-minimum-bid-price-requirement\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alzamend-neuro-has-regained-compliance-with-nasdaqs-minimum-bid-price-requirement\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20220922005370r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20220922005370r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alzamend-neuro-has-regained-compliance-with-nasdaqs-minimum-bid-price-requirement\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Alzamend Neuro Has Regained Compliance with Nasdaq’s Minimum Bid Price Requirement\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Alzamend Neuro Has Regained Compliance with Nasdaq's Minimum Bid Price Requirement - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/alzamend-neuro-has-regained-compliance-with-nasdaqs-minimum-bid-price-requirement\/","og_locale":"en_US","og_type":"article","og_title":"Alzamend Neuro Has Regained Compliance with Nasdaq's Minimum Bid Price Requirement - Market Newsdesk","og_description":"Alzamend Neuro Has Regained Compliance with Nasdaq’s Minimum Bid Price Requirement ATLANTA–(BUSINESS WIRE)–Alzamend Neuro, Inc. (Nasdaq: ALZN) (\u201cAlzamend\u201d), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer\u2019s disease (\u201cAlzheimer\u2019s\u201d), bipolar disorder, major depressive disorder (\u201cMDD\u201d) and post-traumatic stress disorder (\u201cPTSD\u201d), today announced that it has received a notification letter (the \u201cCompliance Notice\u201d) from the Listing Qualifications Staff of the Nasdaq Stock Market, LLC (\u201cNasdaq\u201d) dated September 21, 2022, informing the Company that it has regained compliance with Nasdaq Listing Rule 5550(a)(2) (the \u201cMinimum Bid Price Requirement\u201d) and the matter is closed. As previously announced, on June 22, 2022, Alzamend received a notification letter from Nasdaq stating that the Company was not in compliance with … Continue reading \"Alzamend Neuro Has Regained Compliance with Nasdaq’s Minimum Bid Price Requirement\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/alzamend-neuro-has-regained-compliance-with-nasdaqs-minimum-bid-price-requirement\/","og_site_name":"Market Newsdesk","article_published_time":"2022-09-22T12:04:11+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20220922005370r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alzamend-neuro-has-regained-compliance-with-nasdaqs-minimum-bid-price-requirement\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alzamend-neuro-has-regained-compliance-with-nasdaqs-minimum-bid-price-requirement\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Alzamend Neuro Has Regained Compliance with Nasdaq’s Minimum Bid Price Requirement","datePublished":"2022-09-22T12:04:11+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alzamend-neuro-has-regained-compliance-with-nasdaqs-minimum-bid-price-requirement\/"},"wordCount":585,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alzamend-neuro-has-regained-compliance-with-nasdaqs-minimum-bid-price-requirement\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20220922005370r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alzamend-neuro-has-regained-compliance-with-nasdaqs-minimum-bid-price-requirement\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/alzamend-neuro-has-regained-compliance-with-nasdaqs-minimum-bid-price-requirement\/","name":"Alzamend Neuro Has Regained Compliance with Nasdaq's Minimum Bid Price Requirement - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alzamend-neuro-has-regained-compliance-with-nasdaqs-minimum-bid-price-requirement\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alzamend-neuro-has-regained-compliance-with-nasdaqs-minimum-bid-price-requirement\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20220922005370r1&sid=flmnd&distro=nx&lang=en","datePublished":"2022-09-22T12:04:11+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alzamend-neuro-has-regained-compliance-with-nasdaqs-minimum-bid-price-requirement\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/alzamend-neuro-has-regained-compliance-with-nasdaqs-minimum-bid-price-requirement\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alzamend-neuro-has-regained-compliance-with-nasdaqs-minimum-bid-price-requirement\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20220922005370r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20220922005370r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alzamend-neuro-has-regained-compliance-with-nasdaqs-minimum-bid-price-requirement\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Alzamend Neuro Has Regained Compliance with Nasdaq’s Minimum Bid Price Requirement"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/687960","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=687960"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/687960\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=687960"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=687960"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=687960"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}